A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML

Clinical trial NCT05641259 · UNKNOWN

Trial details

NCT number: NCT05641259
Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD.
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myeloid Leukemia Myelodysplastic Syndromes Chronic Myelomonocytic Leukemia

Start date: 2023-02-14
Primary completion: 2024-12-31
Enrollment: 198

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.